Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00053287
Recruitment Status : Completed
First Posted : January 28, 2003
Last Update Posted : June 10, 2010
National Cancer Institute (NCI)
Information provided by:
Case Comprehensive Cancer Center

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : January 2007
  Actual Study Completion Date : March 2007